Myriad Genetics Inc
NASDAQ:MYGN
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Myriad Genetics Inc
NASDAQ:MYGN
|
US |
|
R
|
RCF Acquisition Corp
F:GY0
|
US |
|
W
|
Wells Fargo & Co
LSE:0R2F
|
US |
|
F
|
FirstEnergy Corp
LSE:0IPB
|
US |
|
P
|
Polyus PJSC
LSE:PLZL
|
RU |
|
C
|
Cirrus Logic Inc
XBER:CRU
|
US |
|
C
|
Compagnie d'entreprises CFE SA
LSE:0O2T
|
BE |
|
S
|
Sinotruk Hong Kong Ltd
OTC:SHKLF
|
CN |
|
Ionis Pharmaceuticals Inc
LSE:0JDI
|
US |
|
I
|
Ishii Iron Works Co Ltd
TSE:6362
|
JP |
|
Palace Banquet Holdings Ltd
HKEX:1703
|
HK |
|
O
|
Ortivus AB
STO:ORTI B
|
SE |
|
Federal National Mortgage Association
LSE:0IL0
|
US |
|
B
|
Baozun Inc
HKEX:9991
|
CN |
|
Harvest Gold Corp
XTSX:HVG
|
CA |
|
A
|
AIC Mines Ltd
SWB:HLS
|
AU |
Myriad Genetics Inc
Myriad Genetics makes genetic tests that help doctors understand a patient’s risk for certain diseases and choose treatment more precisely. Its core products are laboratory tests in areas such as hereditary cancer, women’s health, and some pharmacogenomic tests that look at how a person may respond to a medicine. The company sells these tests through physicians, hospitals, and health systems, and it gets paid when the tests are ordered and processed. The business is built around turning DNA analysis into a clinical service. Patients do not buy a box or a device; instead, their samples are sent to Myriad’s labs, where the company runs the test and returns an interpreted report to the doctor. That makes Myriad more of a specialty diagnostics provider than a traditional medical product company. Myriad also works with drug makers on companion diagnostics and research programs that link a therapy to the right patient group. In that part of the business, it helps biopharma companies develop and validate genetic tests that support drug use. This mix of direct clinical testing and partner work gives Myriad a role at the point where genetics, diagnosis, and treatment decisions meet.
Myriad Genetics makes genetic tests that help doctors understand a patient’s risk for certain diseases and choose treatment more precisely. Its core products are laboratory tests in areas such as hereditary cancer, women’s health, and some pharmacogenomic tests that look at how a person may respond to a medicine. The company sells these tests through physicians, hospitals, and health systems, and it gets paid when the tests are ordered and processed.
The business is built around turning DNA analysis into a clinical service. Patients do not buy a box or a device; instead, their samples are sent to Myriad’s labs, where the company runs the test and returns an interpreted report to the doctor. That makes Myriad more of a specialty diagnostics provider than a traditional medical product company.
Myriad also works with drug makers on companion diagnostics and research programs that link a therapy to the right patient group. In that part of the business, it helps biopharma companies develop and validate genetic tests that support drug use. This mix of direct clinical testing and partner work gives Myriad a role at the point where genetics, diagnosis, and treatment decisions meet.
Revenue Beat: Q4 revenue was $209.8 million, above the high end of guidance, with full-year 2025 revenue at $824.5 million.
Growth Drivers: MyRisk hereditary cancer test and Prolaris saw double-digit volume growth; GeneSight and oncology segments also posted solid gains.
Profitability: Q4 adjusted EBITDA reached $14.3 million and adjusted EPS was $0.04, both showing improvement.
2026 Guidance Reaffirmed: Full-year 2026 revenue is expected between $860–880 million with gross margins of 68–69% and no material MRD revenue contribution assumed.
Product Pipeline: Major product launches expected in 2026, including AI-enabled Prolaris, Precise MRD for multiple cancers, and FirstGene prenatal panel.
Prenatal Rebuild: Prenatal testing volumes declined due to earlier order management issues but are expected to recover starting in Q2 2026.
Cost Discipline: Operating expenses declined year-over-year, with investments redirected to sales and R&D ahead of new launches.
